Avadel Pharmaceuticals $143.7 Million Exchangeable Senior Notes Offering

Davis Polk advised the initial purchasers on a Rule 144A offering by Avadel Finance Cayman Limited, a wholly owned subsidiary of Avadel Pharmaceuticals plc, of $143.7 million aggregate principal amount of its 4.50% exchangeable senior notes due 2023.

Headquartered in Dublin, Ireland, Avadel Pharmaceuticals plc is a branded specialty pharmaceutical company committed to providing solutions for overlooked and unmet medical needs through patient-focused, innovative products. 

The Davis Polk capital markets team included partner Sophia Hudson and associate Roohi Gupte. The Davis Polk equity derivatives team included partner John M. Brandow and associate Mark J. DiFiore. The tax team included partner Po Sit and associate Gil Savir. Counsel David R. Bauer and associates Paul S. Lee and Tilak Koilvaram provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.